Integer (NYSE:ITGR) Rating Reiterated by Benchmark

Benchmark reissued their buy rating on shares of Integer (NYSE:ITGR) in a report issued on Friday, Benzinga reports. They currently have a $130.00 price objective on the medical equipment provider’s stock.

A number of other equities analysts have also issued reports on ITGR. Bank of America raised shares of Integer from a neutral rating to a buy rating and boosted their target price for the stock from $105.00 to $135.00 in a research report on Monday, April 15th. Citigroup increased their target price on shares of Integer from $118.00 to $124.00 and gave the company a neutral rating in a research note on Wednesday, May 22nd. Truist Financial began coverage on Integer in a research note on Wednesday, May 15th. They set a buy rating and a $137.00 price target on the stock. Oppenheimer began coverage on Integer in a research report on Tuesday, July 16th. They issued an outperform rating and a $135.00 price objective for the company. Finally, KeyCorp boosted their price objective on Integer from $123.00 to $139.00 and gave the company an overweight rating in a research report on Tuesday, April 9th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of Moderate Buy and an average price target of $133.86.

Integer Stock Down 1.2 %

NYSE ITGR traded down $1.30 during trading on Friday, reaching $110.47. The company’s stock had a trading volume of 119,762 shares, compared to its average volume of 332,633. The stock has a market capitalization of $3.70 billion, a PE ratio of 38.67, a PEG ratio of 1.70 and a beta of 1.11. The business has a 50-day moving average price of $118.63 and a 200-day moving average price of $113.87. The company has a current ratio of 3.29, a quick ratio of 1.96 and a debt-to-equity ratio of 0.73. Integer has a 1-year low of $69.40 and a 1-year high of $130.15.

Integer (NYSE:ITGR) last issued its quarterly earnings data on Thursday, July 25th. The medical equipment provider reported $1.30 earnings per share for the quarter, topping analysts’ consensus estimates of $1.24 by $0.06. The business had revenue of $436.20 million during the quarter, compared to analysts’ expectations of $437.00 million. Integer had a net margin of 6.31% and a return on equity of 11.48%. Integer’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.14 earnings per share. On average, research analysts forecast that Integer will post 5.31 earnings per share for the current fiscal year.

Insider Activity at Integer

In other news, Director Jean M. Hobby sold 11,960 shares of the stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $119.66, for a total transaction of $1,431,133.60. Following the sale, the director now directly owns 2,280 shares of the company’s stock, valued at $272,824.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Integer news, Director Jean M. Hobby sold 11,960 shares of the stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $119.66, for a total value of $1,431,133.60. Following the transaction, the director now owns 2,280 shares of the company’s stock, valued at $272,824.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP John A. Harris sold 312 shares of the stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $113.00, for a total transaction of $35,256.00. Following the completion of the sale, the executive vice president now owns 1,157 shares in the company, valued at $130,741. The disclosure for this sale can be found here. Insiders sold 28,396 shares of company stock valued at $3,391,070 over the last ninety days. 2.00% of the stock is owned by insiders.

Institutional Trading of Integer

A number of large investors have recently made changes to their positions in the company. GAMMA Investing LLC increased its holdings in shares of Integer by 60.9% in the second quarter. GAMMA Investing LLC now owns 375 shares of the medical equipment provider’s stock worth $43,000 after acquiring an additional 142 shares in the last quarter. Blue Trust Inc. raised its holdings in Integer by 483.3% during the 4th quarter. Blue Trust Inc. now owns 455 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 377 shares during the period. Principal Securities Inc. bought a new position in Integer in the fourth quarter valued at approximately $67,000. Headlands Technologies LLC acquired a new position in shares of Integer in the first quarter valued at approximately $106,000. Finally, Innealta Capital LLC bought a new stake in shares of Integer during the second quarter worth $110,000. Institutional investors own 99.29% of the company’s stock.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.